Plaque Psoriasis

Investigators highlighted the cardiovascular safety of systemic treatments for psoriasis such as methotrexate and tumor necrosis factor inhibitors.

This analysis highlights bimekizumab’s impact on psoriasis clearance compared to ustekinumab, secukinumab, and adalimumab.

This announcement regarding the new sNDA for roflumilast cream in pediatric patients with psoriasis follows positive findings from the MUSE study.

In this analysis, investigators looked at the importance of skin clearance and daily time trade off (dTTO) among adult patients living with chronic hand eczema (CHE).

This analysis looked at a Hispanic patient cohort, systematically linking specific trichoscopic patterns with clinical outcomes related to scalp psoriasis.

This analysis suggests that this AI model effectively classifies skin irritation in patch tests, allowing for quicker and more accurate dermatologic assessments.

These findings on teledermatology highlight its effectiveness as a potential solution for disparities in dermatology care within rural communities.

These data on roflumilast cream 0.3% highlight the medication’s efficacy and safety in pediatric patients aged 2 - 11 years.

This study compared the N-NAIL diagnostic tool to NAPSI, highlighting results among patients with nail psoriasis.

This review highlights phase 3 and long-term data on deucravacitinib therapy for patients with plaque psoriasis.

The investigators present pooled findings from the SUNSHINE and SUNRISE trials assessing secukinumab therapy for HS.

In this analysis, evidence which supports a shift in clinical practice using Chinese herbal medicine was explored for atopic dermatitis.

This cohort study suggests that patients with HS treated with adalimumab have an increased risk of infection compared to those with psoriasis.

A study reveals that upadacitinib dose adjustments in atopic dermatitis enhance treatment personalization.

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

The G-EPOSS study demonstrated the long-term impacts of guselkumab on patients’ psoriasis symptoms, sexual impairment, and perceived stigmatization.

Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.

Recent interview- and survey-based research has quantified the extent to which GPP impacts patients, examining both symptoms and mental health outcomes.

This systematic review and meta-analysis found that biologic switching was shown to be safe and effective among patients with psoriasis.

This summary of dermatology news coverage from the month of August 2025 highlights some of the most notable stories in this medical subfield.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

News coverage from DERM 2025 in the field of psoriasis is highlighted in this post-conference summary.

This interview with Song at DERM2025 highlights recent phase 3 data on risankizumab for genital and scalp psoriasis.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.